Your browser doesn't support javascript.
loading
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema, Parneet; Cho, Byoung Chul; Freitas, Helano; Provencio, Mariano; Chen, Yuh Min; Kim, Sang-We; Wu, Yi-Long; Passaro, Antonio; Martin, Claudio; Tiseo, Marcello; Chang, Gee-Chen; Park, Keunchil; Solomon, Benjamin; Burghuber, Otto; Laskin, Janessa; Wang, Ziping; Lee, Sung Yong; Hu, Yanping; Vansteenkiste, Johan; Zhang, He-Long; Hanrahan, Emer; Geldart, Thomas; Taylor, Rosemary; Servidio, Leslie; Li, Jingyi; Marinis, Filippo de.
Afiliação
  • Cheema P; William Osler Health System, University of Toronto, Toronto, ON, L6R 3J7, Canada.
  • Cho BC; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
  • Freitas H; Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, 01509-001, Brazil.
  • Provencio M; Department of Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, IDHIPSA, Universidad Autónoma de Madrid, 28222, Madrid, Spain.
  • Chen YM; Department of Chest Medicine, Taipei Veterans General Hospital, & School of Medicine, National Yang-Ming Medical University, 112, Taipei, Taiwan.
  • Kim SW; Department of Oncology, Brain Tumor Center, Center for Personalized Cancer Medicine, Lung Cancer Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, & Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China.
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, 71013, Italy.
  • Martin C; Department of Oncology, Instituto Alexander Fleming, Buenos Aires, C1426, Argentina.
  • Tiseo M; Department of Medicine & Surgery, University of Parma, & Medical Oncology Unit, University Hospital of Parma, Via Gramsci, 14, Parma, 43126, Italy.
  • Chang GC; School of Medicine, & Institute of Medicine, Chung Shan Medical University, Division of Pulmonary Medicine, Taichung, 40201, Taiwan.
  • Park K; Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, 40201, Taiwan.
  • Solomon B; Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung, 40705, Taiwan.
  • Burghuber O; Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea.
  • Laskin J; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia.
  • Wang Z; Department of Respiratory & Critical Care Medicine, & Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, & Sigmund Freud University Medical School, Vienna, 1140, Austria.
  • Lee SY; Division of Medical Oncology, BC Cancer, Vancouver, V5Z 4E6, Canada.
  • Hu Y; Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, V6T 1Z4, Canada.
  • Vansteenkiste J; Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, 100142, People's Republic of China.
  • Zhang HL; Department of Internal Medicine, Division of Pulmonary, Allergy, & Critical Care Medicine, Korea University Guro Hospital, Seoul, 08308, Republic of Korea.
  • Hanrahan E; Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, 430079, People's Republic of China.
  • Geldart T; Respiratory Oncology Unit, University Hospitals KU Leuven, Herestraat 49, B-3000, Leuven, Belgium.
  • Taylor R; Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710024, People's Republic of China.
  • Servidio L; Department of Medical Oncology, St Vincent's University Hospital, & Cancer Trials Ireland, Dublin, D04 T6F4, Ireland.
  • Li J; Department of Oncology, University Hospitals Dorset, Bournemouth, BH7 7DW, UK.
  • Marinis F; Biometrics & Information Sciences, AstraZeneca, Cambridge, CB2 0AA, UK.
Future Oncol ; 19(1): 61-75, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36656302
Osimertinib is a drug that blocks the activity of a protein called EGFR on cancer cells, reducing their growth and spread. ASTRIS is the largest real-world study that evaluated the outcomes with osimertinib treatment for patients with advanced non-small-cell lung cancer (NSCLC), and the EGFR T790M mutation, who had received previous treatment for their cancer. There were 3014 patients included in this study. The main aim of this study was to measure the time at which half of the patients were still alive after starting osimertinib treatment, this was 22.8 months. The study also measured the time at which half of the patients had experienced worsening (progression) of their cancer (11.1 months) and the time when half of the patients had stopped receiving osimertinib treatment (13.5 months). None of the patients experienced any unexpected side effects of the treatment. These data are consistent with those observed in comparable clinical trials with osimertinib, supporting the use of osimertinib treatment for patients with advanced NSCLC and the EGFR T790M mutation after their initial cancer treatment has stopped working.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article